Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors. In each of the studies, results of which are to be presented in poster sessions at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., multi-platform tumor profiling via Caris Molecular Intelligence enabled cataloging of biomarkers as potential therapeutic targets in various subtypes of gastrointestinal, hepatic, gynecologic and renal cancers.
Caris Molecular Intelligence is a multi-platform tumor profiling service that includes gene sequencing (Next-Generation Sequencing [NGS] and Sanger), protein expression analysis (Immunohistochemistry [IHC]), and gene copy number and translocation analysis (Chromogenic or Fluorescence in situ Hybridization [CISH or FISH]). Investigators used these methods to examine tumor samples for patterns of biomarker expression that may yield insights into selection of novel therapeutic options for patients with rare and/or aggressive cancer subtypes.
"Although research advances have enhanced our understanding of rare and aggressive cancer subtypes, patients living with these malignancies have few therapeutic options," said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. "The latest cataloging analyses demonstrate that Caris Molecular Intelligence can facilitate the molecular characterization of these subtypes, as well as the identification and selection of treatment regimens that specifically target the biomarkers detected in individual patients' tumors."